A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers

Inclusion Criteria: * Healthy male subjects between 18 and 35 years of age, both inclusive. * Body weight between 50.0 and 100.0 kg, both inclusive. * Body mass index (BMI) between 18.0 and 29.9 kg/m2, both inclusive. * Written informed consent for study participation obtained before undergoing any study specific procedures. Exclusion Criteria: * Subjects at increased cardiovascular risk. * Any clinical sign or known history of atherosclerosis or thromboembolic events. * A subject considered at high risk of thromboembolic events confirmed either from history or by thrombophilia screening test. * Subjects with significant elevation of cholesterol level. * Renal dysfunction. * Overt bleeding. * Smokers with positive cotinine test at screening. * Participation in any other trial investigating a procoagulant within the last six months prior to screening. * Known or suspected hypersensitivity to the investigational medicinal product (IMP), or to any excipients of the IMP. * Contraindications to Warfarin (Coumadin®).